RESEARCH · TESAMORELIN
Tesamorelin: The GHRH Analogue, the GH/IGF-1 Axis and the Published Clinical Studies
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). Unlike growth hormone itself, a GHRH analogue acts upstream, at the pituitary, which is why it has been studied as a way to restore pulsatile growth hormone (GH) secretion. This article summarises the published clinical literature, where it is thin, and general handling background for laboratories. Our earlier tesamorelin post is a short product FAQ; this one is a literature overview. PurixLab’s Tesamorelin 5mg is a lyophilized research vial supplied for laboratory research use only.
Mechanism: a stabilised GHRH(1-44) analogue
Tesamorelin is described in the literature as a stabilised analogue of human GHRH(1-44) [1,2]. One stated rationale is that GH secretion is reduced in patients with excess visceral adiposity [1]. In a study of 13 healthy men treated for two weeks, tesamorelin increased mean overnight GH, GH peak area and basal GH secretion, and raised IGF-I by 181 μg/L, while fasting glucose and insulin-stimulated glucose uptake were not significantly changed [1].
The phase 3 HIV-lipodystrophy trials
- Pivotal trial (NEJM 2007). In 412 patients with HIV and abdominal fat accumulation, visceral adipose tissue (VAT) fell by 15.2% in the tesamorelin group and rose by 5.0% with placebo over 26 weeks. Triglycerides decreased by 50 mg/dL versus an increase of 9 mg/dL, and IGF-I rose by 81.0% versus a 5.0% fall. Glycaemic measures did not differ, but more tesamorelin patients withdrew because of an adverse event [3].
- Pooled analysis. Across two phase 3 trials (806 patients, 2:1 randomisation), VAT fell by 24 cm² versus a 2 cm² rise at week 26 (treatment effect −15.4%), and IGF-I rose by 108 versus −7 ng/mL. In patients continued to week 52, VAT reductions were maintained, and no clinically meaningful glucose differences were seen [4].
- Regulatory context. A 2012 pharmacotherapy review states that the US FDA approved tesamorelin in November 2010 for HIV-associated lipodystrophy, and lists cost and a lack of long-term safety and adherence data as limitations [5].
- Recent syntheses. A 2026 meta-analysis of five randomised trials reported significant reductions in VAT (mean difference −27.71 cm²), trunk fat and hepatic fat, with no significant change in subcutaneous fat or BMI [6]. Another 2026 meta-analysis of four trials (909 patients) found VAT reduction (−21.47 cm²; I² = 74%), noted growth-hormone-related adverse effects, and called for data on longer treatment, dose–response and durability [7].
Liver fat and metabolic studies
In a randomised trial that enrolled 61 people with HIV and NAFLD, 12 months of tesamorelin reduced hepatic fat fraction by an absolute 4.1 percentage points versus placebo (35% versus 4% reached <5%), with no differences in glucose or HbA1c; injection-site complaints were more common with tesamorelin [8]. A follow-up analysis of paired liver biopsies from that trial reported increased expression of oxidative-phosphorylation gene sets and decreased expression of inflammation and cell-division gene sets with tesamorelin [9]. In 53 people with type 2 diabetes, 12 weeks of tesamorelin did not alter insulin response or glycaemic control [10].
Cognition: early and mixed
A 20-week placebo-controlled study in 152 older adults, including adults with mild cognitive impairment, reported a favourable effect on a cognitive composite (P = 0.03 intention-to-treat) and a 117% rise in IGF-1 [2]. A later 73-person phase 2 trial in people with HIV was open-label with no placebo arm and found no significant between-group difference in neurocognitive change, although waist circumference fell more with tesamorelin [11].
What remains unknown
- Population. Most of the randomised evidence comes from adults with HIV on antiretroviral therapy [3,4,6]; evidence outside this group is limited and exploratory [2,11].
- Long-term effects. Reviewers cite limited long-term safety, optimal-dosing and durability data [5,7].
- IGF-1 and GH-axis effects. IGF-I rose substantially in the trials above that reported it, for example by 81.0% in the pivotal HIV trial and 117% in older adults [3,2]; the long-term implications of sustained elevation were not addressed in the abstracts reviewed here.
- Research vs approved product. The clinical findings above come from regulated clinical trials conducted under medical supervision. They say nothing about the content, purity or stability of any other material, including a research-grade lyophilized vial.
General laboratory storage background
Laboratories should always follow the product label, any batch documentation and their own approved procedures. As general background, peptide suppliers’ technical guides describe broadly similar practice for lyophilized (freeze-dried) peptides:
- Keep it dry, dark and cold. Lyophilized peptides should be kept away from heat, light and moisture; for longer-term storage, guides commonly recommend about −20 °C [12,13].
- Avoid condensation. Let a cold vial reach room temperature, ideally in a desiccator, before opening, then reseal promptly [13].
- Limit freeze–thaw cycles. Aliquoting by planned experiment reduces freeze–thaw cycles and air exposure [12].
- Solutions are short-lived. Peptides in solution have a much shorter shelf life than the dry powder [12,13].
This is general laboratory information, not a protocol, and it contains no instructions for human use.
Tesamorelin 5mg at PurixLab
Tesamorelin 5mg: a labelled lyophilized research vial with 5mg per vial, C$119 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/tesamorelin-5mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Codes: WELCOME10 takes 10% off eligible orders below C$400; PURIX20 takes 20% off eligible orders of C$400 or more before discount and tax. One offer per order; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Stanley TL, Chen CY, Branch KL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-8. PubMed 20943777 · PMC3038486 · doi:10.1210/jc.2010-1587
- Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-9. PubMed 22869065 · PMC3764914 · doi:10.1001/archneurol.2012.1970
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70. PubMed 18057338 · doi:10.1056/NEJMoa072375
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304. PubMed 20554713 · doi:10.1210/jc.2010-0490
- Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012;46(2):240-7. PubMed 22298602 · doi:10.1345/aph.1Q629
- Badran AS, Helal A, Shata KS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. PubMed 41545261 · doi:10.1016/j.orcp.2026.01.002
- Ditta AM, Naeem RM, Sami MM, et al. Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis. J Int Assoc Provid AIDS Care. 2026;25:23259582261475549. PubMed 42538058 · PMC13428105 · doi:10.1177/23259582261475549
- Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PubMed 31611038 · PMC6981288 · doi:10.1016/S2352-3018(19)30338-8
- Fourman LT, Billingsley JM, Agyapong G, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020;5(16):e140134. PubMed 32701508 · PMC7455119 · doi:10.1172/jci.insight.140134
- Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017;12(6):e0179538. PubMed 28617838 · PMC5472315 · doi:10.1371/journal.pone.0179538
- Ellis RJ, Vaida F, Hu K, et al. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. J Infect Dis. 2025;231(5):1230-1238. PubMed 39813152 · doi:10.1093/infdis/jiaf012
- GenScript. Peptide Storage and Handling Guidelines (technical resource). GenScript
- AAPPTec. Handling and Storage of Peptides — FAQ (technical resource). AAPPTec